Foghorn Therapeutics Inc. announced advancements in their clinical and preclinical programs, focusing on FHD-909 (LY4050784), a selective SMARCA2 inhibitor currently in a Phase 1 trial targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback